These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 23209717)

  • 1. Placebo cohorts in phase-3 MS treatment trials - predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case data.
    Stellmann JP; Neuhaus A; Herich L; Schippling S; Roeckel M; Daumer M; Martin R; Heesen C
    PLoS One; 2012; 7(11):e50347. PubMed ID: 23209717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Explaining temporal trends in annualised relapse rates in placebo groups of randomised controlled trials in relapsing multiple sclerosis: systematic review and meta-regression.
    Steinvorth SM; Röver C; Schneider S; Nicholas R; Straube S; Friede T
    Mult Scler; 2013 Oct; 19(12):1580-6. PubMed ID: 23471144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time-patterns of annualized relapse rates in randomized placebo-controlled clinical trials in relapsing multiple sclerosis: a systematic review and meta-analysis.
    Nicholas R; Straube S; Schmidli H; Pfeiffer S; Friede T
    Mult Scler; 2012 Sep; 18(9):1290-6. PubMed ID: 22422808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in annualized relapse rates in relapsing-remitting multiple sclerosis and consequences for clinical trial design.
    Nicholas R; Straube S; Schmidli H; Schneider S; Friede T
    Mult Scler; 2011 Oct; 17(10):1211-7. PubMed ID: 21586489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cladribine vs other drugs in MS: Merging randomized trial with real-life data.
    Signori A; Saccà F; Lanzillo R; Maniscalco GT; Signoriello E; Repice AM; Annovazzi P; Baroncini D; Clerico M; Binello E; Cerqua R; Mataluni G; Perini P; Bonavita S; Lavorgna L; Zarbo IR; Laroni A; Pareja-Gutierrez L; La Gioia S; Frigeni B; Barcella V; Frau J; Cocco E; Fenu G; Clerici VT; Sartori A; Rasia S; Cordioli C; Stromillo ML; Di Sapio A; Pontecorvo S; Grasso R; Barone S; Barrilà C; Russo CV; Esposito S; Ippolito D; Landi D; Visconti A; Sormani MP
    Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 32801167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
    Roskell NS; Zimovetz EA; Rycroft CE; Eckert BJ; Tyas DA
    Curr Med Res Opin; 2012 May; 28(5):767-80. PubMed ID: 22462530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation.
    Melendez-Torres GJ; Auguste P; Armoiry X; Maheswaran H; Court R; Madan J; Kan A; Lin S; Counsell C; Patterson J; Rodrigues J; Ciccarelli O; Fraser H; Clarke A
    Health Technol Assess; 2017 Sep; 21(52):1-352. PubMed ID: 28914229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of relapse rate in MS clinical trials.
    Held U; Heigenhauser L; Shang C; Kappos L; Polman C;
    Neurology; 2005 Dec; 65(11):1769-73. PubMed ID: 16344520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early initiation of fingolimod reduces the rate of severe relapses over the long term: Post hoc analysis from the FREEDOMS, FREEDOMS II, and TRANSFORMS studies.
    Haas J; Jeffery D; Silva D; Meier DP; Meinert R; Cohen J; Hartung HP
    Mult Scler Relat Disord; 2019 Nov; 36():101335. PubMed ID: 31557679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing changes in relapse rates in multiple sclerosis.
    Inusah S; Sormani MP; Cofield SS; Aban IB; Musani SK; Srinivasasainagendra V; Cutter GR
    Mult Scler; 2010 Dec; 16(12):1414-21. PubMed ID: 20810517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials.
    Martinelli Boneschi F; Rovaris M; Johnson KP; Miller A; Wolinsky JS; Ladkani D; Shifroni G; Comi G; Filippi M
    Mult Scler; 2003 Aug; 9(4):349-55. PubMed ID: 12926839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world annualized relapse rates from contemporary multiple sclerosis clinics in the UK: a retrospective multicentre cohort study.
    Papathanasiou A; Hibbert A; Tallantyre E; Harding K; Selvam AP; Morgan M; Quainton C; Talaei M; Arun T; Ingram G; Law GR; Evangelou N
    Neurol Sci; 2023 Oct; 44(10):3629-3635. PubMed ID: 37208584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab for relapsing-remitting multiple sclerosis.
    He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches.
    Berardi A; Siddiqui MK; Treharne C; Harty G; Wong SL
    Curr Med Res Opin; 2019 Aug; 35(8):1371-1378. PubMed ID: 30786783
    [No Abstract]   [Full Text] [Related]  

  • 15. Changing EDSS Progression in Placebo Cohorts in Relapsing MS: A Systematic Review and Meta-Regression.
    Röver C; Nicholas R; Straube S; Friede T
    PLoS One; 2015; 10(9):e0137052. PubMed ID: 26327532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A composite score to predict short-term disease activity in patients with relapsing-remitting MS.
    Sormani MP; Rovaris M; Comi G; Filippi M
    Neurology; 2007 Sep; 69(12):1230-5. PubMed ID: 17875911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
    Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY).
    Cohan SL; Moses H; Calkwood J; Tornatore C; LaGanke C; Smoot KE; Meka V; Okwuokenye M; Hotermans C; Mendoza JP; Mann MK; Meltzer LA
    Mult Scler Relat Disord; 2018 May; 22():27-34. PubMed ID: 29524759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seasonal patterns of relapse and disability in Danish MS patients: A population-based cohort study.
    Elser HC; Koch-Henriksen N; Magyari M
    Mult Scler Relat Disord; 2021 Apr; 49():102739. PubMed ID: 33450501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach.
    Sormani MP; Bonzano L; Roccatagliata L; Cutter GR; Mancardi GL; Bruzzi P
    Ann Neurol; 2009 Mar; 65(3):268-75. PubMed ID: 19334061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.